---
title: "Kiniksa Pharmaceuticals CSO Resigns and Shifts to Advisor"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284944421.md"
description: "Kiniksa Pharmaceuticals announced the resignation of Chief Strategy Officer Eben Tessari, effective May 15, 2026, to pursue another executive role in the life sciences sector. His departure is not due to any disagreements. Tessari will transition to a consulting role until May 15, 2027, advising on strategic matters. The current analyst rating for Kiniksa (KNSA) is a Buy with a price target of $59.00, supported by strong financial performance but tempered by premium valuation risks."
datetime: "2026-05-01T21:55:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284944421.md)
  - [en](https://longbridge.com/en/news/284944421.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284944421.md)
---

# Kiniksa Pharmaceuticals CSO Resigns and Shifts to Advisor

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Kiniksa Pharmaceuticals ( (KNSA) ) has shared an announcement.

On April 30, 2026, Kiniksa Pharmaceuticals announced that Chief Strategy Officer Eben Tessari had decided to resign effective May 15, 2026, to pursue another executive role in the life sciences industry, with the company stating his departure was not due to any disagreement over operations, policies, or practices. Upon leaving his executive post, Tessari will transition into a consulting role through May 15, 2027, advising on strategic and operational matters and serving as a special advisor to the Science and Research Committee, a move that helps preserve continuity in Kiniksa’s strategic direction while capping his compensated consulting work at 20 hours per month.

The most recent analyst rating on (KNSA) stock is a Buy with a $59.00 price target. To see the full list of analyst forecasts on Kiniksa Pharmaceuticals stock, see the KNSA Stock Forecast page.

**Spark’s Take on KNSA Stock**

According to Spark, TipRanks’ AI Analyst, KNSA is a Outperform.

The score is driven primarily by strong financial performance (profitability, cash generation, and a low-leverage balance sheet) and a positive earnings-call setup with reaffirmed 2026 guidance and continued commercial momentum. Offsetting factors are premium valuation (high P/E, no dividend support) and technical overextension (RSI in overbought territory and slightly negative MACD), which increase near-term pullback risk.

To see Spark’s full report on KNSA stock, click here.

**More about Kiniksa Pharmaceuticals**

Kiniksa Pharmaceuticals International, plc operates in the life sciences and biopharmaceutical industry, focusing on developing and commercializing therapies for patients with unmet medical needs. The company leverages scientific research and strategic development to advance its portfolio and maintain its positioning within the competitive healthcare market.

**Average Trading Volume:** 695,705

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $4.14B

See more insights into KNSA stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [KNSA.US](https://longbridge.com/en/quote/KNSA.US.md)

## Related News & Research

- [Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Raised to Hold at Zacks Research](https://longbridge.com/en/news/287057945.md)
- [Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Strong Q1 Results And Raised Revenue Guidance](https://longbridge.com/en/news/285144274.md)
- [Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 | WVE Stock News](https://longbridge.com/en/news/286925108.md)
- [16:52 ETNexusTek Named a Contender in ISG Provider Lens® Life Sciences Digital Services 2026 Report](https://longbridge.com/en/news/286818120.md)
- [Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment | ACHV Stock News](https://longbridge.com/en/news/286952863.md)